Rigetti Computing (RGTI) · Deep analysis

Report previewRGTI.USReport date Last updated
← Back to reports
Report contents
01

Business model

Business model: an unproven hardware bet funded by equity

Rigetti sells superconducting quantum computers, and the people who pay for them are spending research money. The customer is a government program office, a national laboratory, a university group or a corporate advanced-research team buying access to a technology that does not yet beat classical machines on useful problems. No buyer is displacing an existing compute budget line; each is buying an option on future capability, so the sale is won on technical credibility and roadmap, not on price per operation. That makes Rigetti a research pipeline with a capital-intensive hardware manufacturer attached, and it sits squarely in the unproven stage.

Revenue arrives in three shapes with different economics. A system sale is a one-off capital purchase: lumpy, negotiated, and followed by years of low-margin support and upgrade work. Cloud access is usage-based, small, and strategically useful mainly because it lets a researcher try the machine before an agency buys one. Development contracts pay for engineering against milestones. The second and third shapes are close to funded R&D; only the first resembles a product sale. Reported revenue therefore says less about progress than it appears to: one delivery can double a quarter, and a contract extension can mask a stalled pipeline. The FY2025 10-K's MD&A is where that mix is disclosed, and contract timing is the first thing to check before reading anything into a single quarter's growth.

The structural choice is vertical integration. Rigetti designs and fabricates its own superconducting chips instead of buying them. In a market with no volume, that puts capital and depreciation into fabrication capacity ahead of demand, the classic small-company trap. What it buys in return is specific: a shorter design-build-measure loop, and that loop is the rate-limiting step in quantum hardware. The fixed cost is worth carrying only if in-house fabrication delivers measurable device improvements faster than rivals who outsource. Steady gains in published fidelity would make the fab an advantage; a slipping cadence would make it overhead with a depreciation schedule.

Competition is not mainly commercial yet. Groups working in trapped ions, neutral atoms and photonics chase the same government and enterprise research dollars, and the scoreboard is public: two-qubit gate fidelity, qubit count, and demonstrations of error correction. Because the buyer can read those numbers, Rigetti's differentiation is engineering cadence rather than brand or distribution, and the relevant comparison is against competitors with far larger balance sheets. Bargaining power sits mostly with the purchaser: procurement is slow, specification-heavy, and often sole-source only where Rigetti is one of a few vendors able to deliver a superconducting system built in-house. Demand is concentrated in U.S. federal and university research budgets, with smaller allied-government programs abroad. That concentration reflects the stage of the market, not a execution failure, but it ties revenue to appropriations cycles and to a handful of program decisions.

Funding is where the model touches a shareholder most directly. The FY2025 10-K cover reports 332,150,557 shares outstanding at March 1, 2026 and a $3.82 billion non-affiliate market value at $11.86 on June 30, 2025. A valuation of that size against a business this early is an option price, not a discounted revenue stream, and the option is financed by selling equity. The listed warrants, exercisable at $11.50, bring in cash when the stock is above the strike and dilute holders who paid more. The per-share claim on any eventual quantum business shrinks with each raise, so technical progress has to outrun share issuance for the equity to hold its value.

What would overturn the central judgment, that this is an option rather than a business, is a repeat purchase. A commercial buyer who is not a research program ordering a second system, or a cloud arrangement with disclosed paid usage, would show demand that is not grant-funded curiosity. So far the evidence only shows superconducting systems being sold into research budgets; it does not show a commercial buyer base forming. The uncomfortable corollary: if device metrics keep improving while contract awards stay flat, the technology is progressing and the business is not, which is worse for equity holders than a technical setback accompanied by rising orders.

Questions worth following

  • Can Rigetti book system sales from commercial buyers rather than research agencies?

    A commercial order book would mean quantum hardware is becoming a purchase rather than a grant, which changes revenue durability, pricing power and how much equity funding the roadmap needs. If demand stays confined to agencies, revenue remains tied to appropriation cycles.

  • Will Rigetti demonstrate error-corrected qubits ahead of better-funded rivals?

    Error correction is the gate between laboratory hardware and any commercially useful machine. Falling behind would strand the fabrication investment, push research buyers toward competing modalities, and undermine the option value that currently supports the equity.

  • Can cloud access turn into a paying channel for Rigetti?

    Cloud distribution lets researchers use a Rigetti machine without buying one, which can widen the funnel into system sales or become a low-revenue demo channel. Which one it becomes determines whether Rigetti needs a direct sales force or can ride partners' distribution.

02

Financial quality

Financial quality: cash burn is the only hard number

Earnings quality: Weak. Rigetti is a pre-commercial quantum-hardware company with annual revenue under $10 million, so most standard ratios either explode or change sign from quarter to quarter. Operating cash flow was negative in every period in the table, and free cash flow has widened to about $40 million in the latest quarter once capital spending is included. The balance sheet is the strong part: no borrowings, and, as the company reported on its November 10, 2026 third-quarter call, $497.1 million of cash and investments at September 30. That buys years of research at the current burn. It does not establish that the research will earn a return.

Reported losses swing on marks, not customers

In the third quarter of 2025 Rigetti booked a $0.20 billion net loss against an operating loss of roughly $0.02 billion. In the first quarter of 2026 the sign flipped: $0.03 billion of net income against a similar operating loss and $0.02 billion of cash used in operations. Net margin went from -10,322% to +2,895% and ROE from -43% to +26% for what was, operationally, the same business. Operating losses barely moved between those quarters, so the swing sits below the operating line; the non-operating section of each 10-Q is where to confirm which items drove it.

The consequence is practical. EPS, net margin and ROE cannot be used to track this company, and any screen showing a profitable quarter is reacting to an accounting mark. Cash used in operations, holding in a $10 million to $20 million band per quarter, is the stable measure of progress.

Gross margin tracks mix, not pricing power

Gross margin ran 30.0%, 31.4%, 20.7%, -92.1%, -28.1%, 42.6% and 60.7% across the seven quarters shown, with full-year figures of 52.8% in FY2024 and -86.1% in FY2025. A company booking about $1.4 million of hardware and research access in a quarter cannot hold a stable margin: whether one system or one contract lands determines how much of the fixed fab, cryogenics and engineering cost inside cost of revenue gets covered. The 78% and 77% margins of FY2022 and FY2023 came on similarly tiny revenue, which shows how much the mix drives the line. The recovery to 60.7% is real, but gross profit of roughly $0.9 million still covered only about 3% of a $30 million operating loss, so margin alone will not close the gap.

The equity, not debt, funds the work

Financing inflows of $0.17 billion in FY2024 and $0.44 billion in FY2025 dwarf the $0.06 billion to $0.08 billion annual free cash outflow. Most of the FY2025 investing outflow of $0.40 billion went into investments, not plant: capital spending derived from the gap between operating and free cash flow was about $0.02 billion. Total assets of $0.62 billion against $0.08 billion of liabilities, a 5.3 current ratio and asset turnover of 0.002 describe a company that is mostly a pool of financial assets with a research operation attached. At FY2025's pace of roughly $80 million a year, the reported cash covers six years; at the latest quarter's $40 million free cash outflow, closer to three. Solvency is not the near-term risk. Dilution is, and each raise moves the payoff further out unless revenue arrives.

What needs checking
  • Revenue recognition. Guidance of about $20 million for FY2026, against $1.4 million in the third quarter and nine-month growth of 110%, depends on one customer accepting one system in the fourth quarter. If it slips, both the growth claim and the 60% margin slip with it.
  • Receivables. Quarterly receivables turnover fell from 1.25 in Q2 2026 to 0.36 in Q3 2026, implying well over 200 days of sales outstanding. On a base this small, a single unpaid agency or research invoice does that; the aging schedule and whether revenue is booked before acceptance need reading.
  • Cost of revenue content. The negative-margin quarters mean the P&L absorbed costs a scaled manufacturer would spread over far more units. How much is depreciation and idle fab capacity determines whether 60% is structural or a mix accident.
  • Government money. The $100 million Department of Commerce agreement is a cash-flow offset carrying a minority, non-controlling government equity stake, and the related R&D still runs through the income statement. Milestone conditions, termination rights and whether the award displaces commercial sales belong in the same review.
Annual metrics

USD bn unless noted; values as reported and rounded, so sub-$10 million lines appear below $0.01. Q3 FY2026 is a three-month interim and is not comparable with the annual columns.

MetricFY2021FY2022FY2023FY2024FY2025Q3 FY2026Assessment
Revenue0.010.010.010.010.01<0.01Very weak: no scale
Gross margin (%)23.578.176.752.8-86.160.7Weak: mix-driven
Net margin (%)-466.6-545.9-625.5-1,862.7-3,050.4-222.3Very weak
ROE (%)300.8-89.3-57.8-170.2-64.3-0.6Not meaningful
ROA (%)-79.6-57.2-41.3-90.4-45.5-0.5Very weak
Liabilities/assets (%)254.115.415.255.5n/dn/dAdequate: no borrowings
Current ratio (x)1.937.103.7117.4237.425.29Strong, largely idle cash
Operating cash flow-0.03-0.06-0.05-0.05-0.06-0.02Very weak
Free cash flow-0.04-0.08-0.06-0.06-0.08-0.04Very weak
Capex (derived)0.010.020.010.010.020.02Heavy against revenue
Quarterly metrics

USD bn unless noted; single-quarter figures, parentheses mark negative values. Net PP&E is not broken out for any period, so capex is derived from operating minus free cash flow.

MetricQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026AssessmentTrend
Revenue<0.01<0.01<0.01<0.01<0.010.01<0.01Tiny and lumpyErratic
Gross margin (%)30.031.420.7-92.1-28.142.660.7Mix-drivenImproving
Net income0.04-0.04-0.20-0.020.03-0.05(<0.01)Non-operating swingsNot meaningful
Total assets0.270.640.630.670.650.650.62Mostly financialStable
Total liabilities0.060.080.260.120.070.110.08No debtStable
Current ratio (x)18.841.639.237.47.03.95.3StrongFalling
Operating cash flow-0.01-0.02-0.01-0.01-0.02-0.02-0.02Very weakPersistently negative
Free cash flow-0.02-0.02-0.02-0.02-0.02-0.03-0.04Very weakWorsening

Questions worth following

  • How long can Rigetti fund operations at the current cash burn?

    Runway decides whether Rigetti reaches its 2028 qubit targets without another equity raise. A longer runway preserves the option value of the technology; a shorter one forces financing on whatever terms the market offers, which is the main route by which existing holders lose.

  • Can Rigetti hold gross margin above 50% as system sales scale?

    Gross margin moved from negative 92% to positive 61% within four quarters on revenue under $10 million. If the improvement survives larger hardware shipments, the cost base is scalable. If it reverses as volume grows, the business needs far more revenue to cover fixed fab and cryogenics costs.

  • How much of Rigetti's reported earnings swings come from fair-value marks?

    Quarterly net income moved from a $0.20 billion loss to a $0.03 billion profit while operating losses barely changed. Isolating the non-cash items shows what the operating business actually earns and whether reported results will ever track the cash burn that funds it.

Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.

Go beyond the preview

Continue reading the full report

  1. Key risksWhat could break the investment case
  2. Valuation and margin of safetyWhat the current price assumes, and how much room for error it leaves
  3. SummaryOur overall judgement and what to watch next

Free to sign up · 20 research points · unlocking this report uses 10

20 points cover 2 full reports. No card needed.

Research reflects its generation date. Preview the first two modules.

More on Rigetti Computing Inc